Short description
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Description
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Sioux Falls, South Dakota, United States, North America
Founded on
June 1, 2014
Exited on
October 25, 2021
Went public on
October 25, 2021
Stock symbol
SABS
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, Cannot Access, Noaccess, Noway Youcantaccess, Uh Ohhhh, Uh Ohhhh, Noaccess, No Way, Noaccessforu, Uh Ohhhh, Noaccess, Cannot Access, Nopepepe
Sign in for full access
Founders
Eddie Sullivan, Edward Hamilton